Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rovalpituzumab tesirine

- PMLiVE

Reckitt Benckiser backtracks on Merck OTC unit

Ends negotiations to add to consumer health division

Novartis building

Novartis gets US nod for lung cancer relapse therapy Zykadia

Second ALK inhibitor to be approved after Pfizer’s Xalkori

Sanofi reception

Sanofi won’t take part in mega-deal trend

CEO says French firm will stick to bolt-on acquisitions

- PMLiVE

Forest Labs agrees $1.46bn deal to buy Furiex

Gains access to promising IBS drug eluxadoline

- PMLiVE

Pfizer confirms interest in AstraZeneca megamerger

Says it has twice tried to engage in merger talks with big pharma rival

- PMLiVE

Mylan raises offer for Meda to $9bn

US generics looks to increases broaden portfolio with Swedish firm

- PMLiVE

Star Group merges with Vox

The marketing communications will absorb ad agency Calcium NYC

- PMLiVE

Allergan resists Valeant’s advances

Threatens to derail proposed $45bn merger

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

- PMLiVE

Valeant offers $45.7bn for Botox firm Allergan

Trend for major pharma deals continues

- PMLiVE

Pfizer rumoured to be after AstraZeneca

Is this the return of the pharma mega-merger?

Novartis building

Novartis pays $16bn for GSK’s oncology portfolio

Swiss company strikes series of deals, including one to step away from vaccines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links